Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19806050 | 0.79 | ESR1 (0.33) | ESR1ESR2CNR2 | |
| SCHEMBL23209739 | 0.68 | ESR2 (0.71) | ESR1ESR2 | |
| SCHEMBL14220022 | 0.65 | EPHX1 (0.43) | ESR1ESR2EPHX1 | |
| SCHEMBL14219386 | 0.65 | EPHX1 (0.43) | ESR1ESR2EPHX1 | |
| SCHEMBL25467236 | 0.64 | PDE2A (0.38) | CNR2PDE2ACASR | |
| SCHEMBL22845292 | 0.64 | ESR1 (0.39) | ESR1ESR2CNR1CNR2 | |
| SCHEMBL14219459 | 0.64 | PDPK1 (0.38) | ESR1ESR2 | |
| SCHEMBL14219401 | 0.64 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL14219321 | 0.64 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL19522474 | 0.63 | ESR1 (0.41) | ESR1ESR2CNR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | ESR1 1302/4885ESR2 308/4885CNR1 2007/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | ESR1 1302/4885ESR2 308/4885CNR1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.